LMB and/or its derivatives have been recognized as a novel class of cancer therapeutics through highly specific and potent inhibition of CRM1, a NES-dependent nuclear exporter [8], [9], [10], [11], [12], [19], [20]. The gene discussed is NES; the disease is cancer.